Premium
Efficacy and safety of first‐ or second‐line irinotecan, cisplatin, and mitomycin in mesothelioma
Author(s) -
Fennell Dean A.,
Steele Jeremy P.C.,
Shamash Jonathan,
Evans Marie T.,
Wells Paula,
Sheaff Michael T.,
Rudd Robin M.,
Stebbing Justin
Publication year - 2006
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.22366
Subject(s) - medicine , irinotecan , mesothelioma , neutropenia , chemotherapy , cisplatin , mitomycin c , toxicity , oncology , surgery , confidence interval , progression free survival , gastroenterology , cancer , pathology , colorectal cancer
BACKGROUND. Malignant pleural mesothelioma (MPM) is a rapidly progressive lethal tumor. Treatment options remain limited and the outcome in recurrent disease is poor. METHODS. A Phase II open‐label noncomparative study was conducted to assess the safety and efficacy of the triplet combination irinotecan, cisplatin, and mitomycin‐C (IPM) chemotherapy in untreated patients and in those with previous exposure to chemotherapy. RESULTS. In 62 patients an objective response rate of 25% was observed. In the first‐line setting progression‐free survival measured 6.4 months (95% confidence interval [CI]: 4.5–7.3) and overall survival was 10.8 months (95% CI: 7.9–13.7). In the second‐line setting progression‐free survival was 7.3 months (95% CI: 3.4–11.2) and overall survival was also 7.3 months (95% CI: 4.8–9.8). Psychosocial well‐being improved during chemotherapy and the main toxicity observed was neutropenia (40%). CONCLUSIONS. IPM appeared to have a reasonable response rate with an acceptable toxicity profile in the first‐ and second‐line treatment of MPM. Cancer 2007. © 2006 American Cancer Society.